Posted by Michael Wonder on 13 Apr 2018
Fresenius Kabi announces new approval and immediate availability of daptomycin for injection
12 April 2018 - Fresenius Kabi announced today it has received FDA approval for daptomycin for injection and the product is available immediately for customers in the United States.
Daptomycin for Injection is an antibiotic and a generic alternative to Cubicin.
The U.S. FDA approved Fresenius Kabi’s ANDA for daptomycin on 11 April 2018. The approval provides Fresenius Kabi and its customers an additional source of this important antibiotic. Fresenius Kabi also offers daptomycin for Injection produced by a third party under a separate, previously approved ANDA.
